Evidence map›Paper›PMID 41462333›Full record

ArticleDiabetology & metabolic syndrome2025

The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study.

Chia-Huei Chu, Yi-Chao Hsu, Chang-Yin Lee, Liang-Yu Lin, Wu-Lung Chuang, Heng-Jun Lin, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chia-Huei Chu *Department of Otolaryngology - Head Neck Surgery, MacKay Memorial Hospital, Taipei, Taiwan.
Yi-Chao HsuDepartment of Audiology and Speech-Language Pathology, Mackay Medical University, New Taipei City, Taiwan.
Chang-Yin LeeCollege of Medicine, The School of Chinese Medicine for Post Baccalaureate, I-Shou University (Yancho Campus), Kaohsiung, Taiwan.
Liang-Yu LinDivision of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Wu-Lung ChuangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua City, 500, Taiwan.
Heng-Jun LinManagement Office for Health Data, Medical University Hospital, China Medical University, Taichung, 404327, Taiwan.
Cheng-Li LinManagement Office for Health Data, Medical University Hospital, China Medical University, Taichung, 404327, Taiwan.
Der-Yang ChoTranslational Cell Therapy Center, Department of Medical Research, Medical University Hospital, Taichung, 404327, Taiwan.
Kuang-Hsi ChangDepartment of Long-Term Care, College of Nursing, Asia University, Taichung, 413, Taiwan. kuanghsichang@gmail.com.

Funding

China Medical University Hospital DMR-111-105; DMR-112-087; DMR-113-009; DMR-113-156; DMR-114-046; DMR-114-139Taiwan Ministry of Health and Welfare Clinical Trial Center MOHW113-TDU-B-212-114009
6 · The paper itself

Abstract

abatract

backgroundSensorineural hearing loss (SNHL) is a common but underrecognized complication of type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was associated with favorable renal and cardiovascular outcomes beyond glycemic control, but their impact on auditory outcomes remains unclear.

methodsWe conducted a nationwide cohort study using Taiwan's National Health Insurance Research Database (2000-2021). Patients with T2DM who received SGLT2i for ≥ 90 days were compared with matched non-users. Propensity score matching was applied 1:1 based on demographic, clinical, and treatment characteristics. The primary outcome was the incidence of SNHL, confirmed by audiometric testing.

resultsA total of 381,592 patients with type 2 diabetes mellitus (T2DM) were included. Compared with non-users, SGLT2i users exhibited a significantly lower risk of SNHL (adjusted hazard ratios (aHRs) = 0.84; 95% CI: 0.75-0.94). Subgroup analyses confirmed a consistent lower risk across sex, age, urbanization, and comorbidity strata. Notably, long-term SGLT2i use (≥ 366 days) showed a strong dose-response association with reduced SNHL risk (aHR = 0.32; 95% CI: 0.27-0.39).

conclusionSGLT2i use in T2DM patients is associated with a reduced risk of SNHL, particularly with sustained therapy. These findings highlight a potential association between SGLT2i use and a lower risk of auditory complications in diabetes, underscoring the importance of considering hearing health within comprehensive diabetes management.

Indexed as

Auditory outcomesPopulation-based studySensorineural hearing lossSGLT2 inhibitorType 2 diabetes

Identifiers

PMID41462333
PMCPMC12751864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.